SUNNYVALE, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today that Michael K. Inouye, senior vice president of corporate and commercial development, will participate on the “Novel Cancer Targets” panel on Thursday, December 13th at 9:00 a.m. EST as part of the 2007 RBC Capital Markets Healthcare Conference at the Westin New York at Times Square in New York City.
To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com. The archived version of the webcast will be available on the company’s website for one month.
About Pharmacyclics
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from non-small cell lung cancer was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R), Xcytrin(R) and the “pentadentate” logo(R) are registered trademarks of Pharmacyclics, Inc.
CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330; or Danielle
Bertrand of WeissComm Partners, +1-415-946-1056, for Pharmacyclics, Inc.
Web site: http://www.pharmacyclics.com/
